Chemocentryx reported $28.18M in Selling and Administration Expenses for its second fiscal quarter of 2022.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Selling And Administration Expenses Change
Abbvie ABBV:US USD 3.3B 174M
Alnylam Pharmaceuticals ALNY:US USD 235.86M 65.88M
Amgen AMGN:US USD 1.29B 40M
AstraZeneca AZN:LN USD 3.35B 280M
Bayer BAYN:GR EUR 4.08B 393M
Biogen BIIB:US USD 563.3M 9.3M
Biomarin Pharmaceutical BMRN:US USD 216.82M 19.98M
Bristol Myers Squibb BMY:US USD 1.93B 147M
GlaxoSmithKline GSK:LN GBP 1.97B 13M
Glaxosmithkline GSK:US GBP 1.97B 13M
Johnson & Johnson JNJ:US USD 6.09B 137M
Macrogenics MGNX:US USD 15.35M 1.69M
Merk MRK:US USD 2.47B 13M
Mirati Therapeutics MRTX:US USD 60.8M 6.57M
Novartis NOVN:VX USD 3.4B 185M
Omeros OMER:US USD 12.2M 1.72M
Pfizer PFE:US USD 3.54B 345M
Roche Holding ROG:VX 5.64B 899M
Sarepta Therapeutics SRPT:US USD 104.79M 49.53M
Takeda 4502:JP JPY 248.73B 17.25B
Teva Pharmaceutical TEVA:IT USD 777M 72M
YTE INCY:US USD 266.46M 13.18M